애프터마켓
로그인 회원가입
ABVX
ABVX
Abivax ADR
7월 27일 4:00 PM ET (한국 7/28 05:00)
$128.00
+2.30 ▲ +1.83%
🌙 7월 27일 4:10 PM ET (한국 7/28 05:10)
$128.00
+0.00 +0.00%

아비박스(ABVX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$11.2B
미드캡
P/E
-
배당수익률
없음
52주 위치
75%
저점 +95% · 고점 -14%
애널리스트
적극 매수
C
Fundamental health
vs. 미분류 중형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 66%
밸류에이션
데이터 부족
재무 안정
Top 43%
Index -P/E -EPS (ttm) -5.25Insider Own 14.42%Shs Outstand 79.3MPerf Week -2.66%
Market Cap 11.17BForward P/E -EPS next Y 7.24%Insider Trans -Shs Float 74.7MPerf Month 38.57%
Enterprise Value 10.64BPEG -EPS next Q -0.96Inst Own 48.91%Short Float 5.38%Perf Quarter 11.73%
Income -0.39BP/S -EPS this Y 31.67%Inst Trans -10.31%Short Ratio 1.94Perf Half Y 4.81%
Sales 0.00BP/B 20.5EPS next 5Y -ROA -95.27%Short Interest 4.02MPerf YTD -5.08%
Book/sh 6.24P/C 19.72EPS past 3/5Y -17.73% -12.77%ROE -158.32%52W High -14% ($148.83)Perf Year 92.51%
Cash/sh 6.49P/FCF -Sales past 3/5Y -ROIC -72.44%52W Low 94.91% ($65.67)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -73.77%Gross Margin -Volatility(W/M) 4.28% 4.41%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 6.87Perf 10Y -
Dividend Ex-Date -Quick Ratio 8.25EPS Q/Q 17.42%Profit Margin -RSI (14) 51.38Recom 1.28
Dividend Gr. 3/5Y -Current Ratio 8.25Sales Q/Q -SMA20 -4.28% ($133.72)Beta 1.17Target Price $162.06
Payout -Debt/Eq 0.08Earnings 2026/5/22SMA50 8.52% ($117.95)Rel Volume 0.32Prev Close $125.7
Employees 69LT Debt/Eq 0.08EPS/Sales Surpr. 26.35% 277.34%SMA200 10.15% ($116.21)Avg Volume(3M) 2.07MPrice $128
IPO 2023/10/20Option/Short Yes/YesTrades 7542Volume 662,324Change 1.83%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Abivax ADR (ABVX) Investment Analysis

What kind of company is Abivax ADR?

아비박스(ABVX)
Healthcare · Biotechnology
#891 by Market Cap — Mid-Cap

A US-listed American Depositary Receipt (ADR) of a clinical-stage biotech company developing treatments for chronic inflammatory diseases. The company is developing its oral drug candidate, obefazimod—which modulates immune response—for ulcerative colitis. This is a drug development stock whose share price is largely driven by clinical trial results and regulatory approval progress.

Learn more about Abivax ADR →
Market Cap
$11.2B
Approx. KRW 15.3 trillion
⚖️ 4% of Samsung Electronics
Market Cap Rank891
Employees69people
IPO2023/10/20
Current Price$128.00 ≈ 175,360원
NASD · France

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 22일 (금) · 장 마감 후 EPS +26.4% 매출 +277.3%
🔔 Earnings release 2026년 3월 23일 (월) · 장 마감 후 EPS +16.9% 매출 -71.5%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-158.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-95.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-72.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.08
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
8.25
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
8.25
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$162.06
현재가 대비 +26.6%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+7.2%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-0.1%
평균 서프라이즈
2026.05.22
상회
실적 $-0.71 · 예상 $-0.81 +12.8%
2026.03.23
하회
실적 $-1.18 · 예상 $-1.04 -13.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+31.7%
양호
My positionMid-range
Low range Average High range
미분류 중형주 Median 7.3% · Top 41%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+7.2%
평균
My positionMid-range
Low range Average High range
미분류 중형주 Median 15.6% · Bottom 31%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-17.7%
부진
My positionBottom 25%
Low range Average High range
미분류 중형주 Median 18.2% · Bottom 23%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-12.8%
부진
My positionBottom 25%
Low range Average High range
미분류 중형주 Median 6.4% · Bottom 24%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Outperformed the market by +77%p over the past year
ABVX +92.5% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
+76.5%p
well ahead of the market
vs Health Care (XLV)
+72.8%p
well ahead of the sector average
Rank among peers
1-year return Lower-Mid (lower 47%) Based on 76 peers
Current position within 52-week range
Low (-94.9%p) High (-14.0%p)
Current price is 94.9% above the 52-week low and 14.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-45.5%
Annualized volatility
116.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $128.00 below the midline ($133.72). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 3.975 · Signal 5.810 · Hist -1.835. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 51.4 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 22.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
20.50x
✓ Very pricey
My positionBottom 25%
Low range Average High range
Biotechnology 중형주 median 6.81x · Bottom 7% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$162.06 vs. current price +26.6%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership flow shows some pressure
Institutional net selling -10.3% · Short interest moderate 5.4%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-10.3%
Institutions large net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 48.9%
Moderate institutional participation
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 14.4%
Founder/management large holders (strong skin-in-the-game)
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 36.7%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
5.4%
Moderate
Healthcare 중형주 Median 11.3%
Past 90 days Little change
Short interest days to cover
1.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 79.3M주
Float (tradable shares) 74.7M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ABVX

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ABVX ABVX This Stock
$11.2B- 20.5 -158.32% - +1.8%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 아비박스(ABVX)?

아비박스(ABVX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ABVX?

The market cap of ABVX is approximately $11.2B, ranking 891 within its sector.

What is the 52-week high and low for ABVX?

ABVX has recorded a 52-week high of $148.83 and a low of $65.67.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.